Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis.

ABSTRACT:

Background

Recently, the addition of inhaled corticosteroid (ICS) to long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been recommended for patients with COPD who have severe symptoms and a history of exacerbations because it reduces the exacerbations. In addition, a reducing effect on mortality has been shown by this treatment. However, the evidence is mainly based on one large randomized controlled trial IMPACT study, and it remains unclear whether the ICS add-on treatment is beneficial or not. Recently, a large new ETHOS trial has been performed to clarify the ICS add-on effects. Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety including ETHOS trial.

Methods

We searched rel

SUBMITTER: Koarai A 

PROVIDER: S-EPMC8218448 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature